RayKnowChina Research Map
Shortlist

Not yet recruitingBreast cancerPhase 2

Registered title, quoted from ClinicalTrials.gov

A Prospective, Single-center, Phase II Study of Sacituzumab Tirumotecan in Combination With Pembrolizumab for Neoadjuvant Treatment of Triple-Negative Breast Cancer (TNBC)

An open trial on breast cancer, registered on ClinicalTrials.gov. Led by Yantai Yuhuangding Hospital; 0 other hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 1

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Lead sponsorYantai Yuhuangding Hospital烟台毓璜顶医院YantaiHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT07054242, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 8

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (8 points)Hide the checklist
  1. 18 years to 75 years; sex: all

    Registered eligibility fields

  2. Histologically or cytologically confirmed stage II-III (T1cN1-2 or T2-4N0-2) triple-negative breast cancer (TNBC), defined as:

    Inclusion criterion 1

  3. Previous treatment with immune checkpoint inhibitors (anti-PD-1/L1, anti-CTLA-4) or T-cell targeting therapies.

    Exclusion criterion 3

    Prior Trop-2 directed therapy or topoisomerase I inhibitor treatment.

    Exclusion criterion 4

  4. ECOG performance status 0-1.

    Inclusion criterion 6

  5. Absolute neutrophil count ≥1.5×10⁹/L (no G-CSF support within 14 days)

    Inclusion criterion 8

    Platelets ≥100×10⁹/L (no transfusion within 14 days)

    Inclusion criterion 9

    Hemoglobin >9 g/dL (no transfusion/ESA within 14 days)

    Inclusion criterion 10

    Total bilirubin ≤1.5×ULN

    Inclusion criterion 11

    AST/ALT ≤1.5×ULN

    Inclusion criterion 12

    Alkaline phosphatase ≤2.5×ULN

    Inclusion criterion 13

    Serum creatinine ≤1.5×ULN or CrCl ≥60 mL/min (Cockcroft-Gault)

    Inclusion criterion 14

    INR/PT ≤1.5×ULN

    Inclusion criterion 15

  6. At least one measurable lesion as per RECIST 1.1 criteria.

    Inclusion criterion 5

  7. Other malignancies within 5 years (except adequately treated CIS of cervix, BCC, or cutaneous SCC).

    Exclusion criterion 5

  8. For women of childbearing potential and men with WOCBP partners: agreement to use effective contraception from screening until 6 months post-treatment.

    Inclusion criterion 19

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: stage or severity, as the trial defines it.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07054242, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • Histologically or cytologically confirmed stage II-III (T1cN1-2 or T2-4N0-2) triple-negative breast cancer (TNBC), defined as:
  • Immunohistochemistry (IHC) showing ER and PR <1%
  • HER2-negative per 2028 ASCO-CAP guidelines (IHC 0/1+ or IHC 2+/ISH-)
  • Available tumor tissue sample for biomarker analysis.
  • At least one measurable lesion as per RECIST 1.1 criteria.
  • ECOG performance status 0-1.
  • Adequate organ function as evidenced by:
  • Absolute neutrophil count ≥1.5×10⁹/L (no G-CSF support within 14 days)
  • Platelets ≥100×10⁹/L (no transfusion within 14 days)
  • Hemoglobin >9 g/dL (no transfusion/ESA within 14 days)
  • Total bilirubin ≤1.5×ULN
  • AST/ALT ≤1.5×ULN
  • Alkaline phosphatase ≤2.5×ULN
  • Serum creatinine ≤1.5×ULN or CrCl ≥60 mL/min (Cockcroft-Gault)
  • INR/PT ≤1.5×ULN
  • TSH within normal range (or normal FT3/FT4 if TSH abnormal)
  • Normal cardiac enzymes (isolated abnormalities allowed if clinically insignificant)
  • No prior anti-cancer therapy for current diagnosis.
  • For women of childbearing potential and men with WOCBP partners: agreement to use effective contraception from screening until 6 months post-treatment.
  • Willing and able to comply with study procedures and provide written informed consent.

Exclusion Criteria:

  • LVEF <50% by ECHO/MUGA or significant cardiac disease (NYHA Class III/IV).
  • Prior chemotherapy, targeted therapy, or radiotherapy for current breast cancer.
  • Previous treatment with immune checkpoint inhibitors (anti-PD-1/L1, anti-CTLA-4) or T-cell targeting therapies.
  • Prior Trop-2 directed therapy or topoisomerase I inhibitor treatment.
  • Other malignancies within 5 years (except adequately treated CIS of cervix, BCC, or cutaneous SCC).
  • Severe ocular surface disease (dry eye syndrome, meibomian gland dysfunction, or corneal disorders impairing healing).
  • Known hypersensitivity to study drug components.
  • History of immunodeficiency disorders or organ transplantation.
  • Current or history of:
  • Steroid-requiring interstitial lung disease/pneumoniti Unresolved ILD/pneumonitis on screening imaging

Clinically significant pulmonary conditions including:

  • Recent pulmonary embolism (≤3 months)
  • Severe asthma/COPD/restrictive lung disease
  • Pleural effusion requiring intervention
  • Connective tissue disease with pulmonary involvement
  • Prior pneumonectomy
  • Active autoimmune disease requiring systemic treatment (past 2 years), except:
  • Hormone replacement therapy
  • Physiologic corticosteroid replacement
  • Active infection requiring systemic therapy within 14 days prior to initiation.
  • Uncontrolled comorbidities that may:
  • Compromise patient safety
  • Interfere with study completion
  • Any condition that in the investigator's judgment may:
  • Affect study drug evaluation
  • Compromise safety assessments
  • Interfere with data interpretation
  • Otherwise contraindicate participation

Quoted from ClinicalTrials.gov, NCT07054242, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT07054242, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT07054242